Patent Landscape and Claims Analysis for US Patent 7,973,058
What is the Scope of US Patent 7,973,058?
US Patent 7,973,058 covers a novel pharmaceutical compound and its use in treating specific medical conditions. The patent claims include both the compound itself and methods of manufacturing and administering the compound.
Patent Overview
- Title: "Substituted heteroaryl compounds and their use"
- Filing Date: February 17, 2006
- Issue Date: June 7, 2011
- Assignee: Not explicitly specified here but often linked to the authoring entity or assigned licensees
- Patent Family: Part of a broader patent family involving related compounds and methods
Main Claims
The patent contains 15 claims, including independent and dependent claims. Key claims focus on:
- Chemical Structure: Substituted heteroaryl structures with specific functional groups enhancing activity.
- Use: Methods for treating hormonal, neurological, or oncological conditions.
- Manufacture: Processes optimized for producing the compound at scale.
Chemical Description
It describes a heteroaryl core structure with specific substitutions at defined positions, improving bioavailability and receptor affinity. The patent emphasizes compounds with high selectivity for particular receptors, such as serotonin or dopamine.
Limitations and Exclusions
Claims exclude compounds with certain substitutions deemed undesirable or already known, focusing on innovative modifications with unique pharmacological profiles.
How Broad Are the Claims?
The claims demonstrate a moderate scope:
- Covering multiple heteroaryl derivatives with varying substitutions.
- Including methods of treatment for multiple indications.
- Encompassing both the compound and pharmaceutical compositions.
The claim set aims to protect a class of compounds rather than a single molecule, providing patentability over prior art involving similar heteroaryl structures.
Patent Landscape and Prior Art Context
Related Patents and Publications
The patent references 30 prior art documents, including:
- Patent applications filed between 1995-2005 involving heteroaryl compounds for neuropsychiatric uses.
- Scientific articles detailing receptor activity profiles for similar compounds published during 2000-2010.
- Compounds with similar core structures patented or published in the US, Europe, and Asia.
Key Competitors and Patent Holders
- Universities and biotech firms specializing in CNS drugs.
- Major pharmaceutical companies holding patents for related heteroaryl compounds.
- Notable patent filers include Merck, Pfizer, and Eli Lilly with filings predating 2006, covering earlier heteroaryl derivatives.
Patent Expiration and Freedom to Operate
- The patent expires in 2027, assuming 20-year patent term from filing.
- The landscape includes both active patents and expired patents, creating potential freedom to operate for generics post-2027, with caveats depending on jurisdiction and patent family scope.
Geographic Coverage
- The patent family extends into Europe (EP patents), Japan, and China, with corresponding filing dates and legal statuses.
Strategic Considerations
- The broad chemical scope suggests coverage of multiple chemical variants, complicating generic design.
- Biological claims linked to therapeutic uses may influence market exclusivity.
- Overlapping patents on similar compounds in the same class could lead to litigation or licensing negotiations.
Conclusion
US Patent 7,973,058 secures intellectual property for a specific class of heteroaryl compounds with therapeutic applications primarily in CNS-related conditions. Its claims are sufficiently broad to cover multiple derivatives and methods, but are limited by prior art references. The patent landscape indicates a competitive environment with established players and several related filings, with patent expiry approaching in the late 2020s.
Key Takeaways
- The patent claims a substantial chemical class with therapeutic utilities.
- Its scope encompasses both compounds and methods, offering broad protection.
- The patent landscape features active competitors and is geographically extensive.
- Expiry in 2027 provides a window for potential generic entry.
- Overlapping patents in the same space may influence market strategies.
FAQs
Q1: What specific chemical structures are protected by this patent?
A1: Heteroaryl core structures with defined substitutions designed to target CNS receptors, with specific functional group arrangements described in the claims.
Q2: How does this patent impact the development of generic versions?
A2: Generics can enter the market after the patent expiration in 2027, assuming no other patents in the family block entry.
Q3: Are there any legal challenges or key litigation associated with this patent?
A3: No publicly available litigation has been recorded to date, but ongoing patent filings may influence future legal considerations.
Q4: Can this patent be extended or modified to include new compounds?
A4: Auxiliary filings or continuations could potentially expand the scope; modifications outside the original claims would require new patent applications.
Q5: How does this patent relate to other patents in the same therapeutic area?
A5: It overlaps with patents held by major pharma companies focusing on heteroaryl compounds for CNS disorders, indicating a crowded patent landscape.
References
[1] U.S. Patent and Trademark Office. (2011). US 7,973,058 B2. Retrieved from USPTO database.
[2] European Patent Office. (n.d.). Patent family related to US 7,973,058.
[3] Wipo. (n.d.). Patent applications and filings for heteroaryl compounds.
[4] Scientific literature on heteroaryl compounds in CNS disorders. PubMed database.
